Actively Recruiting
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
Led by Xiangdong Cheng · Updated on 2024-10-15
150
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
CONDITIONS
Official Title
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology with advanced or metastatic disease that cannot be surgically removed
- HER2 negative
- No prior anti-tumor treatment received
- Planned treatment with chemotherapy combined with immunotherapy
- Aged 18 to 75 years, any gender
- Expected survival of at least 3 months
You will not qualify if you...
- Presence of malignant tumors other than gastric cancer or tumors spread to the stomach from other sites
- Previous anti-tumor treatments including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy
- Severe infections
- History of mental illness preventing cooperation with the study
- Severe heart, liver, kidney, or other serious diseases
- Pregnant or breastfeeding
- HER2 positive
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
X
Xiangdong Cheng Cheng, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here